Ali, Y., Mohammed, A., Ali, F. (2022). Heamodynamic Doppler changes in portal pressure after trans-arterial chemoembolization of hepatocellular carcinoma.. test, 3(1), 389-400. doi: 10.21608/ejmr.2022.226200
Yasmine Ahmed Ali; Ahmed Hesham Mohammed; Faten Mohammed Ali. "Heamodynamic Doppler changes in portal pressure after trans-arterial chemoembolization of hepatocellular carcinoma.". test, 3, 1, 2022, 389-400. doi: 10.21608/ejmr.2022.226200
Ali, Y., Mohammed, A., Ali, F. (2022). 'Heamodynamic Doppler changes in portal pressure after trans-arterial chemoembolization of hepatocellular carcinoma.', test, 3(1), pp. 389-400. doi: 10.21608/ejmr.2022.226200
Ali, Y., Mohammed, A., Ali, F. Heamodynamic Doppler changes in portal pressure after trans-arterial chemoembolization of hepatocellular carcinoma.. test, 2022; 3(1): 389-400. doi: 10.21608/ejmr.2022.226200

Heamodynamic Doppler changes in portal pressure after trans-arterial chemoembolization of hepatocellular carcinoma.

Egyptian Journal of Medical Research
Article 30, Volume 3, Issue 1, January 2022, Pages 389-400    PDF (319.86 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.226200
Authors
Yasmine Ahmed Ali; Ahmed Hesham Mohammed; Faten Mohammed Ali
Diagnostic radiology department, Faculty of Medicine, Beni-Suef University, Egypt.
Abstract
Aim: The goal of this study was to determine changes in portal pressure hemodynamics of HCC patients after their management using transarterial chemoembolization (TACE). Twenty five patients with HCC underwent TACE. Medical history in addition to investigations were carried out including Doppler ultrasound for assessment of portal hypertension (PHT )parameters, and then repeated 3 months after TACE. Results: TACE had resulted in a markedly increased liver vascular index with significant reduction in hepatic artery resistive index following therapy. TACE was accompanied by improvement of PHT parameters. Doppler ultrasound might be used as a reliable and efficient tool for assessment of PHT changes. Conclusion: Locoregional therapy has become increasingly pivotal for HCC patients as a result of advances in approaches, survival benefit, and a favorable safety profile, despite curative measures including surgical resection and liver transplantation are still the gold standard.
Keywords
Portal hypertension; HCC; Doppler ultrasound; TACE
References
  1.  Ferlay J, Shin HR, Bray F, et al. (2010) Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917.
  2. Simpson HN, McGuire BM (2015) Screening and detection of hepatocellular carcinoma. Clin Liver Dis 19(2):295–307.
  3. Bruix J, Gores GJ, Mazzaferro V (2014) Hepatocellular carcinoma:clinical frontiers and perspectives. Gut 63(5):844–855 Simpson HN, McGuire BM (2015) Screening and detection of hepatocellular carcinoma. Clin Liver Dis 19(2):295–307.
  4. Govaere O, Roskams T (2015) Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis 19(2):261–276.
  5. Casado M, Bosch J, Garcı´a-Paga´n JC, et al. (1998) Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114(6):1296–1303.
  6. Sonomura T, Kawai N, Kishi K, et al. (2014) N-butyl cyanoacrylate embolization with blood flow control of an arterioportal shunt that developed after radiofrequency ablation of hepatocellular carcinoma. Korean J Radiol 15(2):250–253.
  7. EASL:   Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., … Vilgrain, V. (2018).  Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182–236.
  8. Matsui O, Kobayashi S, Sanada J, Kouda W, Ryu Y, Kozaka K, et al. 2011 Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging;36:264-272.
  9. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. 2005 Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer;103:299-306.
  10. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. 2009 Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology;252:605-614.
  11. Iwamoto S, Yamaguchi T, Hongo O, Iwamoto H, Sanefuji H. 2010 Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma: a retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma. Cancer;116:393-399.
  12. Kudo, M. (2015). "Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?" Liver cancer 4(3): I-VII.
  13. Shao, W., C. Li, J. Tang, J. Song, Z. Li, J. Sun, Y. Xu, Z. Zheng, J. Cao and L. Zhang (2019 Transarterial). "Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma." Cancer Manag Res 11: 9863-9869.
  14. Xu, Z. and H. Xie (2019). "The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma."  2019: 8619096.
  15. Löschner, C., Nagel, S., Kausche, S., & Teichgräber, U. (2015). Hepatic Arterial Supply in 1297 CT-Angiographies. RöFo - Fortschritte Auf Dem Gebiet Der Röntgenstrahlen Und Der Bildgebenden Verfahren, 187(04), 276–282.
  16. El Sherbiny, W., A. AbdelRahman, M. Diasty and S. W. Shaltout (2016). "Changes in Doppler parameters of portal pressure after interventional management of hepatocellular carcinoma."  41(8): 1532-1538.
  17. Shin, S. W. (2009). "The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma." Korean J Radiol 10(5): 425-434.
  18. Bolognesi, M., D. Sacerdoti, C. Merkel, G. Gerunda, A. Maffei-Faccioli, P. Angeli, R. M. Jemmolo, G. Bombonato and A. Gatta (1996). "Splenic Doppler impedance indices: influence of different portal hemodynamic conditions." Hepatology 23(5): 1035-1040.
  19. Iwakiri, Y. and R. J. Groszmann (2006). "The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule." Hepatology 43(2 Suppl 1): S121-131.
  20. Grant EG, Schiller VL, Millener P, et al. 1992 Color Doppler imaging of the hepatic vasculature. AJR Am J Roentgenol ; 159:943-950.
  21. Zhang, L., Y. Y. Duan, J. M. Li and J. K. Yin (2007). "Hemodynamic features of Doppler ultrasonography in patients with portal hypertension: intraoperative direct measurement of portal pressure in the portal venous system." J Ultrasound Med 26(12): 1689-1696.
  22. Huang, T. L., T. Y. Chen, L. L. Tsang, H. Y. Ou, C. Y. Yu, C. C. Wang, S. H. Wang, C. C. Lin, Y. W. Liu, C. C. Yong, K. W. Chiu, H. L. Eng, B. Jawan, Y. F. Cheng and C. L. Chen (2012). "Hemodynamics of portal venous stenosis before and after treatment in pediatric liver transplantation: evaluation with Doppler ultrasound." Transplant Proc 44(2): 481-483.
  23. Benvegnù, L., & Alberti, A. (2001). Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Research, 52(2), 199–207.
  24. Kok, K., Naylor, S. L., & Buys, C. H. C. M. (1997). Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes. Advances in Cancer Research, 27–92.
  25. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. 2005 Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer;103:299-306.
  26. Xu, Z. and H. Xie (2019). "The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma."  2019: 8619096.
  27. Grant EG, Schiller VL, Millener P, et al. 1992 Color Doppler imaging of the hepatic vasculature. AJR Am J Roentgenol ; 159:943-950.
  28. Chan, A. O., M. F. Yuen, C. K. Hui, W. K. Tso and C. L. Lai (2002). "A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma." Cancer 94(6): 1747-1752.
  29. Jeon, S. H., K. S. Park, Y. H. Kim, Y. S. Shin, M. K. Kang, B. K. Jang, W. J. Chung, K. B. Cho and J. S. Hwang (2007). "[Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma]." Korean J Gastroenterol 50(3): 176-182.
  30. Tasneem, A. A., Z. Abbas, N. H. Luck, S. M. Hassan and S. M. Faiq (2013). "Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events." J Pak Med Assoc 63(2): 239-244.
  31. Shao, W., C. Li, J. Tang, J. Song, Z. Li, J. Sun, Y. Xu, Z. Zheng, J. Cao and L. Zhang (2019 Transarterial). "Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma." Cancer Manag Res 11: 9863-9869.
  32. Kaplan, D. E., R. Mehta, K. D'Addeo, T. P. Gade and T. H. Taddei (2018). "Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching." Journal of vascular and interventional radiology : JVIR 29(4): 540-549.e544.
Statistics
Article View: 256
PDF Download: 145